Alemtuzumab and natalizumab: The monoclonal antibody story continues

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 17, Issue 6, 2006, Pages 327-329

  Johnston, B L ^a,c   Conly, J M ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BETA1A INTERFERON; CALICHEAMICIN; CORTICOSTEROID; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; ITRACONAZOLE; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB;

ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIAL; CROHN DISEASE; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION COMPLICATION; INFECTION RISK; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYCOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; SHORT SURVEY;

EID: 33846365674     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/876252     Document Type: Short Survey

References (33)

1. Johnston BL, Conly JM. Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians? Can J Infect Dis Med Microbiol 2006;17:209-12.
2. Waldmann TA. Immunotherapy: Past, present and future. Nat Med 2003;9:269-77.
3. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24.
4. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 2006;81:1361-7.
5. Thursky KA, Worth LJ, Seymour JF, Prince HM, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2005;132:3-12.
6. Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Sem Oncol 2006;33(Suppl 5):S44-52.
7. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 2005;36:797-802.
8. Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006;37:307-10.
9. Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath 'in the bag' as T-cell depletion: The Leiden experience. Bone Marrow Transplant 2006;37:1129-34.
10. Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 2006;33(Suppl 5):S36-43.
11. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005;5:1347-53.
12. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005;80:457-65.
13. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005;80:765-74.
14. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006;19:705-14.
15. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006;81:17-20.
16. Safdar N, Smith J, Knaskinskwi V, Andes D. Infectious complications associated with alemtuzumab (Campath=anti-CD52) in solid organ transplant recipients: A case controlled study. Proceedings of the IDSA 44th Annual Meeting, Toronto, October 12 to 15, 2006 (Abstract 486).
17. Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Dig Liver Dis 2005;37:811-8.
18. Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006;12:171-8.
19. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
20. Miller DH, Khan OA, Sheremata WA, et al; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
21. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon Beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
22. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
23. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
24. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med 2005;353:414-6.
25. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-7.
26. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59:748-54.
27. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
28. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
29. Rudick RA, Stuart WH, Calebresi PA, et al. Natalizumab plus interferon Beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
30. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
31. Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006;354:965-7.
32. Hauser SL, Weiner HL. Natalizumab: Immune effects and implications for therapy. Ann Neurol 2006;59:731-2.
33. Natalizumab (marketed as Tysabri) Information. 〈www.fda.gov/cder/ drug/infopage/natalizumab/default.htm〉 (Version current at November 9, 2006).